Literature DB >> 1718920

Experience with the Peponen capsule in the management of benign prostatic hyperplasia.

A Hamvas1, G Corradi, M Hegedüs, D Frang.   

Abstract

Sixty patients in Stages I and II of benign prostatic hyperplasia were treated with Peponen capsule. Out of them 26 took the drug for 10 months, 22 for at least 7, and 12 for at least 4 months. The daily dosage was 3 x 2 capsules in the first month and 3 x 1 capsule for the rest of the time. On the ground of urodynamic test results and changes in subjective complaints, more than 80% of the patients experienced improvement. The therapy intensified the uroflow, appeased dysuria, the difficult and painful discharge, and reduced the frequency of nocturnal urination.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718920     DOI: 10.1007/bf02549728

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  2 in total

1.  Observations with Bazoton in the management of prostatic hyperplasia.

Authors:  I Romics
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

2.  Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia.

Authors:  G Bartsch; H R Müller; M Oberholzer; H P Rohr
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

  2 in total
  1 in total

1.  Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats.

Authors:  Chetan Nandecha; Alok Nahata; Vinod Kumar Dixit
Journal:  Curr Ther Res Clin Exp       Date:  2010-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.